The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Gregory Karczmar and Milica Medved.
Connection Strength

8.655
  1. Characterization of Effects of Compressed Sensing on High Spectral and Spatial Resolution (HiSS) MRI with Comparison to SENSE. Tomography. 2023 03 19; 9(2):693-705.
    View in: PubMed
    Score: 0.917
  2. High spectral and spatial resolution MRI of prostate cancer: a pilot study. Magn Reson Med. 2021 09; 86(3):1505-1513.
    View in: PubMed
    Score: 0.806
  3. Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. J Magn Reson Imaging. 2017 11; 46(5):1341-1348.
    View in: PubMed
    Score: 0.603
  4. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
    View in: PubMed
    Score: 0.414
  5. Echo-planar spectroscopic imaging (EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE). Magn Reson Med. 2010 Jun; 63(6):1557-63.
    View in: PubMed
    Score: 0.378
  6. Fourier component imaging of water resonance in the human breast provides markers for malignancy. Phys Med Biol. 2009 Oct 07; 54(19):5767-79.
    View in: PubMed
    Score: 0.359
  7. Clinical implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve unilateral full-breast coverage. Magn Reson Imaging. 2010 Jan; 28(1):16-21.
    View in: PubMed
    Score: 0.356
  8. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.278
  9. Fourier components of inhomogeneously broadened water resonances in breast: a new source of MRI contrast. Magn Reson Med. 2004 Jul; 52(1):193-6.
    View in: PubMed
    Score: 0.251
  10. Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI. Magn Reson Med. 2024 Feb 02.
    View in: PubMed
    Score: 0.243
  11. The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging. 2003 Oct; 18(4):442-8.
    View in: PubMed
    Score: 0.238
  12. Standardization of Breast Dynamic Contrast-enhanced MRI Signal with Application to the Assessment of Background Parenchymal Enhancement Rate. Curr Med Imaging. 2023 Mar 06.
    View in: PubMed
    Score: 0.229
  13. Directional and inter-acquisition variability in diffusion-weighted imaging and editing for restricted diffusion. Magn Reson Med. 2022 11; 88(5):2298-2310.
    View in: PubMed
    Score: 0.219
  14. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
    View in: PubMed
    Score: 0.214
  15. Signal intensity form of the Tofts model for quantitative analysis of prostate dynamic contrast enhanced MRI data. Phys Med Biol. 2021 01 22; 66(2):025002.
    View in: PubMed
    Score: 0.197
  16. A compact solution for estimation of physiological parameters from ultrafast prostate dynamic contrast enhanced MRI. Phys Med Biol. 2019 08 07; 64(15):155012.
    View in: PubMed
    Score: 0.178
  17. Low-dose imaging technique (LITE) MRI: initial experience in breast imaging. Br J Radiol. 2019 Nov; 92(1103):20190302.
    View in: PubMed
    Score: 0.177
  18. Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography. 2019 06; 5(2):260-265.
    View in: PubMed
    Score: 0.176
  19. Comparison of arterial input functions measured from ultra-fast dynamic contrast enhanced MRI and dynamic contrast enhanced computed tomography in prostate cancer patients. Phys Med Biol. 2018 01 30; 63(3):03NT01.
    View in: PubMed
    Score: 0.161
  20. Ultrafast Bilateral DCE-MRI of the Breast with Conventional Fourier Sampling: Preliminary Evaluation of Semi-quantitative Analysis. Acad Radiol. 2016 09; 23(9):1137-44.
    View in: PubMed
    Score: 0.143
  21. Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magn Reson Imaging. 2016 Feb; 34(2):197-203.
    View in: PubMed
    Score: 0.137
  22. B1 and T1 mapping of the breast with a reference tissue method. Magn Reson Med. 2016 Apr; 75(4):1565-73.
    View in: PubMed
    Score: 0.133
  23. Comparison of dynamic contrast-enhanced MRI parameters of breast lesions at 1.5 and 3.0?T: a pilot study. Br J Radiol. 2015 May; 88(1049):20150021.
    View in: PubMed
    Score: 0.132
  24. High-resolution diffusion-weighted imaging of the prostate. AJR Am J Roentgenol. 2014 Jul; 203(1):85-90.
    View in: PubMed
    Score: 0.125
  25. Hybrid multidimensional T(2) and diffusion-weighted MRI for prostate cancer detection. J Magn Reson Imaging. 2014 Apr; 39(4):781-8.
    View in: PubMed
    Score: 0.118
  26. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.112
  27. Do we really need contrast agents? Eur J Radiol. 2012 Sep; 81 Suppl 1:S99-100.
    View in: PubMed
    Score: 0.110
  28. Sensitivity to tumor microvasculature without contrast agents in high spectral and spatial resolution MR images. Magn Reson Med. 2009 Feb; 61(2):291-8.
    View in: PubMed
    Score: 0.086
  29. Quantitative analysis of water proton spectral lineshape: a novel source of contrast in MRI. Phys Med Biol. 2008 Sep 07; 53(17):4509-22.
    View in: PubMed
    Score: 0.083
  30. Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
    View in: PubMed
    Score: 0.074
  31. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.063
  32. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med. 2004 Mar; 51(3):487-94.
    View in: PubMed
    Score: 0.061
  33. Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy. Cancers (Basel). 2023 Dec 13; 15(24).
    View in: PubMed
    Score: 0.060
  34. Safely reducing unnecessary benign breast biopsies by applying non-mass and DWI directional variance filters to ADC thresholding. BMC Med Imaging. 2022 09 29; 22(1):171.
    View in: PubMed
    Score: 0.055
  35. Breast MR imaging with high spectral and spatial resolutions: preliminary experience. Radiology. 2002 Aug; 224(2):577-85.
    View in: PubMed
    Score: 0.055
  36. Spectrally inhomogeneous effects of contrast agents in breast lesion detected by high spectral and spatial resolution MRI. Acad Radiol. 2002 Aug; 9 Suppl 2:S352-4.
    View in: PubMed
    Score: 0.055
  37. Physically implausible signals as a quantitative quality assessment metric in prostate diffusion-weighted MR imaging. Abdom Radiol (NY). 2022 07; 47(7):2500-2508.
    View in: PubMed
    Score: 0.054
  38. Robustness of radiomic features of benign breast lesions and hormone receptor positive/HER2-negative cancers across DCE-MR magnet strengths. Magn Reson Imaging. 2021 10; 82:111-121.
    View in: PubMed
    Score: 0.051
  39. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.
    View in: PubMed
    Score: 0.048
  40. Discrimination of benign from malignant breast lesions in dense breasts with model-based analysis of regions-of-interest using directional diffusion-weighted images. BMC Med Imaging. 2020 06 09; 20(1):61.
    View in: PubMed
    Score: 0.047
  41. Spectral characterization of tissues in high spectral and spatial resolution MR images: Implications for a classification-based synthetic CT algorithm. Med Phys. 2017 May; 44(5):1865-1875.
    View in: PubMed
    Score: 0.038
  42. Breast density estimation from high spectral and spatial resolution MRI. J Med Imaging (Bellingham). 2016 Oct; 3(4):044507.
    View in: PubMed
    Score: 0.037
  43. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.036
  44. Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score. AJR Am J Roentgenol. 2016 Sep; 207(3):592-8.
    View in: PubMed
    Score: 0.036
  45. Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging. 2015 Oct; 40(7):2523-8.
    View in: PubMed
    Score: 0.034
  46. Preliminary assessment of dispersion versus absorption analysis of high spectral and spatial resolution magnetic resonance images in the diagnosis of breast cancer. J Med Imaging (Bellingham). 2015 Apr; 2(2):024502.
    View in: PubMed
    Score: 0.033
  47. Residual analysis of the water resonance signal in breast lesions imaged with high spectral and spatial resolution (HiSS) MRI: a pilot study. Med Phys. 2014 Jan; 41(1):012303.
    View in: PubMed
    Score: 0.030
  48. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.030
  49. Potential of computer-aided diagnosis of high spectral and spatial resolution (HiSS) MRI in the classification of breast lesions. J Magn Reson Imaging. 2014 Jan; 39(1):59-67.
    View in: PubMed
    Score: 0.030
  50. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
    View in: PubMed
    Score: 0.024
  51. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
    View in: PubMed
    Score: 0.022
  52. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.021
  53. Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med. 2007 Dec; 58(6):1266-75.
    View in: PubMed
    Score: 0.020
  54. Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging. 2007 Jun; 25(5):593-603.
    View in: PubMed
    Score: 0.019
  55. Multi-slice DCE-MRI data using P760 distinguishes between metastatic and non-metastatic rodent prostate tumors. MAGMA. 2006 Feb; 19(1):15-21.
    View in: PubMed
    Score: 0.017
  56. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med. 2004 Nov; 52(5):1110-7.
    View in: PubMed
    Score: 0.016
  57. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.